Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET) Abstract #997

Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.
Aim(s): To compare the accordance of different imaging techniques and a biomarker in patients with metastatic NET.
Materials and methods: Retrospective analysis of 17 NET patients data, covering MRT/CT, somatostatin receptor scintigraphy, DOPA-PET and Chromogranin A.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Florian Keplinger

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study
Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: dr Sara Massironi
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study
Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Chiara Maria Grana